The Biotechnology Industry Organization (BIO) lauds the Senate for passing a bipartisan budget deal raising discretionary budget caps, which should grant the Food and Drug Administration (FDA) complete access to its user fees for FYs '14 and '15.
The following statement can be attributed to Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO):
"BIO applauds the Senate for its hard work in reaching a bipartisan budget deal, and again we recognize the House for passing the budget deal last week.
"Today's Senate decision to release user fees paid by our members to the FDA will help speed the delivery of breakthrough products and technologies to the patients who need them most.
"Allowing the FDA full access to these privately paid fees will provide the agency with the resources it needs to keep pace with scientific advances while also safeguarding patient safety. Our member companies bring novel medicines, medical devices and diagnostics to patients, and need a fully-funded FDA in order to provide patients with the treatments they need to live longer, healthier lives.
"We look forward to continuing to work with Congress through future budget processes. Also, we call on the House and the Senate to pass both S. 1413, the Pryor/Blunt FDA User Fee Protection Act and H.R. 2725, the Lance/Eshoo FDA SOS Act, to ensure FDA user fees are permanently prevented from being sequestered in the future. Holding back FDA user fees through sequestration puts patients' lives at risk."
((Comments on this story may be sent to email@example.com))